ReviewJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2026
Epigenetic regulation and chromatin organization in cystic fibrosis airways.
Review in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cystic fibrosis (CF) is caused by pathogenic variants of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. CF in the airways is associated with dehydrated and hyperconcentrated mucus, impaired mucociliary transport, and inflammation. Although CF is a genetic disorder, CFTR sequence variations alone may not fully explain its phenotypic variation. Additionally, while pharmacological CFTR modulators that correct CFTR protein function greatly improve clinical outcomes, people with CF treated with modulators can still exhibit abnormal mucus and persistent inflammation compared to non-CF individuals. As such, understanding the regulation of mucus and inflammation remains crucial to full characterization and management of CF. We suggest that non-DNA-sequence-based mechanisms that regulate CFTR, mucus, and inflammation contribute to CF pathogenesis. This review highlights three features of transcriptional regulation known to modify gene expression (DNA methylation, histone modifications, and three-dimensional chromatin organization) and their role in CF airways. For each feature, we discuss current knowledge of their role in regulating CFTR, gel-forming mucin genes, and inflammation in CF contexts. We also highlight exploratory efforts to target epigenetic mechanisms as CF treatment strategies and suggest that epigenetics and chromatin organization offer a rich space for future CF research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.